IP Library Granted Patent US 9,107,419
Granted Patent B2
US 9,107,419 · App. 13/144,286 · Granted Aug 18, 2015

Compositions and methods for treatment or prevention of

Inventors: Joan M. Fallon (Bronxville, NY); Matthew Heil (Sherman, CT); James J. Fallon (Armonk, NY)
Assignee: CURELON LLC
A01N63/02A01N65/00A61K38/465A61K38/47A61K38/4826A61K45/06A61L2/0088A61L2/18A61L2/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,107,419
App. No.
13/144,286
Granted
Aug 18, 2015
Kind
B2
Abstract

Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus . The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.

Claims (16)

1. A method for the treatment or prevention of Staphylococcus aureus infection in a bird or a mammal, comprising administering to the bird or mammal a therapeutically effective amount of an oral pharmaceutical composition comprising digestive enzymes and a pharmaceutically acceptable excipient, wherein the digestive enzymes comprise a protease, an amylase, and a lipase, wherein the pharmaceutical composition is bacteriocidal or bacteriostatic for Staphylococcus aureus , wherein the pharmaceutical composition is formulated for oral administration, and wherein a ratio of total protease to total lipase ranges from about 1:1 to about 20:1.

2. The method of claim 1 , wherein the digestive enzymes comprise pancreatic enzymes.

3. The method of claim 1 , wherein the digestive enzymes comprise pig enzymes.

4. The method of claim 1 , wherein the protease comprises chymotrypsin and trypsin.

5. The method of claim 1 , wherein the digestive enzymes are, independently, derived from an animal source, a microbial source, a plant source, or a fungal source, or are synthetically prepared.

6. The method of claim 1 , wherein the mammal is a pig, horse, cow, dog, cat, monkey, rat, mouse, sheep, goat, or human, and wherein the bird is a chicken, duck, turkey, or goose.

7. The method of claim 5 , where the animal source is a pig pancreas.

8. The method of claim 1 , wherein the ratio of total protease to total lipase ranges from about 4:1 to about 10:1.

9. The method of claim 1 , wherein the pharmaceutical composition is a dosage formulation selected from the group consisting of: pills, tablets, capsules, caplets, sprinkles, emulsions, powders, liquids, gels, and a combination of any thereof.

10. The method of claim 1 , further comprising administering a beta-lactam antibiotic to the bird or mammal.

11. The method of claim 1 , wherein the ratio of total protease to total lipase is about 4:1.

12. The method of claim 1 , wherein the ratio of total protease to total lipase is about 5:1.

13. The method of claim 1 , wherein the ratio of total protease to total lipase is about 7:1.

14. The method of claim 1 , wherein the ratio of total protease to total lipase is about 10:1.

15. The method of claim 1 , wherein the ratio of total protease to total lipase is about 12:1.

16. The method of claim 1 , wherein the pharmaceutical composition comprises about 200 USP units/mg of protease, about 40 USP units/mg of lipase, and about 250 USP units/mg of amylase.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2017
From: CURELON, LLC
To: GALENAGEN, LLC
Reel/Frame 041483/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2011
From: CUREMARK LLC
To: CURELON LLC
Reel/Frame 027312/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2011
From: FALLON, JOAN M.; HEIL, MATTHEW; FALLON, JAMES J.
To: CUREMARK, LLC
Reel/Frame 026737/0870 →
Continuity (4)
Provisional Application 61142714 · Jan 6, 2009
Provisional Application 61153274 · Feb 17, 2009
Provisional Application 61170915 · Apr 20, 2009
Related Publication 20110280853A1 · Nov 17, 2011